CD274 and non-small cell lung carcinoma: In the first-line setting, pembrolizumab is now a standard of care in PD-L1-positive (≥50%) NSCLC (7), while combinations of pembrolizumab or atezolizumab with chemotherapy have shown their superiority over chemotherapy alone, irrespective of PD-L1 expression level (8–10).